1. Academic Validation
  2. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action

Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action

  • Pharmacol Biochem Behav. 2020 Mar:190:172872. doi: 10.1016/j.pbb.2020.172872.
Mei Huang 1 Wenqi He 1 Lakshmi Rajagopal 1 Andrea Kudwa 2 Dimitri E Grigoriadis 2 Herbert Y Meltzer 3
Affiliations

Affiliations

  • 1 Departments of Psychiatry and Behavioral Sciences, Pharmacology, and Physiology, School of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States of America.
  • 2 Neurocrine Biosciences, Inc., San Diego, CA 921302007.
  • 3 Departments of Psychiatry and Behavioral Sciences, Pharmacology, and Physiology, School of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States of America. Electronic address: h-meltzer@northwestern.edu.
Abstract

Valbenazine, a vesicular Monoamine Transporter 2 (VMAT2, SLC18A2) inhibitor, is a newly approved treatment for tardive dyskinesia. VMAT2 is present in the membrane of secretory vesicles and transports dopamine (DA), norepinephrine (NE), serotonin (5-HT), histamine, glutamate (Glu), and GABA into vesicles for presynaptic release. We utilized microdialysis in awake, freely moving mice to determine the effect of NBI-98782, the active metabolite of valbenazine, alone, or in combination with several antipsychotic drugs (APDs), to influence neurotransmitter efflux in the medial prefrontal cortex (mPFC), dorsal striatum (dSTR), hippocampus and nucleus accumbens (NAC); we also compared it with tetrabenazine, the prototypical VMAT2 inhibitor. Acute NBI-98782 and tetrabenazine decreased mPFC, dSTR, hippocampus, and NAC DA, 5-HT, and NE efflux, while increasing that of DOPAC, HVA, and 5-HIAA. Sub-chronic NBI-98782 (7 days) decreased baseline DA and 5-HT efflux in both mPFC and dSTR. NBI-98782 elicited similar effects on neurotransmitter efflux in sub-chronic NBI-98782-treated mice but also enhanced ACh and GABA; the decrease in DA efflux in mPFC and dSTR was not significant in the sc-treated Animals. NBI-98782 suppressed clozapine-, olanzapine- and risperidone-induced DA efflux in both mPFC and dSTR, and ACh efflux in mPFC. NBI-98782 suppressed the haloperidol-induced DA efflux in dSTR, with minimal effect on GABA efflux. NBI-98782 attenuated PCP-induced DA, 5-HT, NE and Glu efflux, and AMPH-induced DA and NE efflux, in both mPFC and dSTR, as well as PCP- and AMPH-induced hyperlocomotion, suggesting possible beneficial antipsychotic effects.

Keywords

Antipsychotic drugs; Microdialysis; NBI-98782; Tardive dyskinesia; Vesicular monoamine transporter 2 inhibitor.

Figures
Products